In a groundbreaking collaboration, XingImaging and SynuSight have been granted support from The Michael J. Fox Foundation for the development of the innovative α-synuclein PET tracer 18F-FD4, aimed at revolutionizing the diagnosis and treatment of Parkinson’s disease. This partnership signifies a crucial advancement in the field of neuroimaging and radiopharmaceutical services, bringing together expertise from both companies to propel the project towards clinical translation.
Parkinson’s disease stands as the second most prevalent neurodegenerative disorder globally, trailing only behind Alzheimer’s disease, affecting more than 10 million individuals. The condition is characterized by the gradual degeneration of dopamine neurons and the accumulation of abnormal α-synuclein aggregates in the brain. These pathological changes lead to a spectrum of motor symptoms like tremors and rigidity, along with non-motor complications such as cognitive decline and olfactory impairments.
The current diagnostic methods for Parkinson’s disease heavily rely on clinical evaluations, often resulting in delayed detection until substantial neuronal damage has already taken place. Early signs of the disease, such as subtle changes in movement patterns and sleep disturbances, frequently overlap with symptoms of other disorders, complicating accurate diagnosis. While existing clinical imaging tools like DATScan offer insights into dopaminergic dysfunction and metabolic alterations, they lack the necessary molecular specificity for biomarkers, impeding timely intervention and the development of effective disease-modifying therapies.
SynuSight’s research and development team has harnessed structural biology techniques to elucidate the molecular structures of α-synuclein fibrils, enabling the precise design of FD4, a cutting-edge PET tracer engineered to selectively target α-synuclein fibrils. Preclinical and early clinical data have demonstrated the tracer’s robust and selective binding to α-synuclein fibrils, allowing for the identification of α-synuclein pathology in the early stages of synucleinopathies. This breakthrough facilitates the implementation of proactive therapeutic strategies for Parkinson’s disease.
Roger Gunn, the Chief Scientific Officer at XingImaging, and Principal Investigator of the project, emphasizes the significance of advancing the development of alpha-synuclein PET tracers for clinical use. He expresses gratitude for the support from The Michael J. Fox Foundation, highlighting the shared commitment to creating a potent PET imaging biomarker that targets the core pathology of Parkinson’s disease. Such a biomarker is poised to enhance our comprehension of the disease, its progression, and will play a pivotal role in evaluating novel treatments through clinical trials.
SynuSight Biotech’s CEO, Roger Fan, expresses deep appreciation for the foundation’s support towards the 18F-FD4 program, citing the superior imaging performance demonstrated in patients with Parkinson’s disease, Multiple System Atrophy (MSA), and Rapid Eye Movement Behavior Disorder (RBD). With the backing of the grant, the companies are well-positioned to accelerate validation efforts through additional clinical studies, unlocking the full potential of 18F-FD4 to drive the development of disease-modifying therapies that can transform disease diagnosis and management on a global scale.
Jamie Eberling, PhD, the Senior Vice President of Research Resources at The Michael J. Fox Foundation, underscores the importance of advancements in alpha-synuclein imaging and highlights the potential of XingImaging and SynuSight Biotech’s F-FD4 program in providing a vital tool for measuring and visualizing brain pathology in Parkinson’s disease.
SynuSight Biotech is dedicated to pioneering innovative diagnostic and therapeutic solutions for neurodegenerative diseases by leveraging cutting-edge scientific expertise and advanced technology platforms. The team specializes in studying the misfolding and aggregation of key proteins implicated in neurodegenerative disorders, such as α-synuclein, tau, and Aβ, utilizing state-of-the-art techniques like Cryo-EM electron diffraction and In-cell NMR spectroscopy to unlock new possibilities for therapeutic molecule development.
Based in New Haven, CT, XingImaging operates with over 24,000 square feet of research space and a team of more than 50 staff members. The company is structured into Clinical, Chemistry, and Imaging Sciences divisions, supported by functions including Regulatory Affairs, Quality Assurance, Imaging, Data Management Services, Information Technology, and Business Operations, ensuring a comprehensive approach to advancing neuroimaging and radiopharmaceutical services.
Takeaways:
– The collaboration between XingImaging and SynuSight, supported by The Michael J. Fox Foundation, represents a significant stride in developing an α-synuclein PET tracer for Parkinson’s disease.
– The 18F-FD4 PET tracer shows promise in selectively targeting α-synuclein fibrils, enabling early detection of synucleinopathies and proactive treatment strategies.
– Advancements in alpha-synuclein imaging hold the potential to revolutionize the diagnosis and management of Parkinson’s disease, benefiting millions of patients worldwide.